Press Releases
Search
-
09 May 2023
Press Release
bioMérieux receives US FDA CLIA-waiver for the BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini
Marcy-l’Étoile (France), May 9th, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, has received U.S. Food and Drug Administration (FDA) Clinical Laboratory Improvement Amendment...
-
27 Apr 2023
Press Release
bioMérieux – First-Quarter 2023 Business Review
Marcy l’Étoile (France), April 27th, 2023 – bioMérieux today releases its business review for the three months ended March 31th, 2023. Consolidated sales totaled €906 million in the first quarter of 2...
-
14 Apr 2023
Press Release
Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement
Oxford, UK and Marcy-l’Etoile, France, 14 April 2023: Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore”), the company delivering a new generation of nanopore-based molecular sensing techn...
-
13 Apr 2023
Press Release
bioMérieux receives US FDA 510(k) clearance for the BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini
Marcy-l’Étoile (France), April 13, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the fast and accura...
-
07 Apr 2023
Press Release
SPECIFIC REVEAL™ Rapid AST System, newly renamed VITEK® REVEAL™, submitted to US FDA for 510(k) clearance
Marcy l’Étoile, France, April 7 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Admini...
-
05 Apr 2023
Press Release
bioMérieux launches BIOFIRE® FIREWORKS™, a cutting-edge, data-driven software solution
Marcy-l’Étoile, France – bioMérieux, a world leader in the field of in vitro diagnostics, launches BIOFIRE® FIREWORKS™, an innovative and integrated software solution for BIOFIRE® Systems optimizing l...
-
10 Mar 2023
Press Release
BioFire Defense partners with BARDA to accelerate development of the SPECIFIC REVEAL™ Rapid AST System
Marcy-l’Étoile, France – bioMérieux, a world leader in the field of in vitro diagnostics, announces that BioFire Defense, LLC, its affiliate and leader in pathogen detection systems for the U.S. Depar...
-
08 Mar 2023
Press Release
bioMérieux 2022 Financial Results
Marcy l’Etoile (France) – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on March 7 under the chairmanship of Alexandre Mérieux and approved the audited...
-
08 Feb 2023
Press Release
US FDA 510(k) Clearance and CLIA-waiver for the fast and innovative BIOFIRE® SPOTFIRE® System
Marcy l’Étoile (France) – February 8th 2023 bioMérieux, a world leader in the field of in vitro diagnostics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laborato...
-
01 Feb 2023
Press Release
MAESTRIA™, a new generation microbiology middleware developed by bioMérieux
bioMérieux, a world leader in the field of in vitro diagnostics, launches MAESTRIA. This new generation middleware for the microbiology laboratory aims at providing a central software tool for the workflow management of all routine activities.
-
20 Dec 2022
Business & Solutions
CE-marking of VIDAS® KUBE™, the next generation system in the VIDAS® immunoassay portfolio
VIDAS® KUBE™ is the next generation automated immunoassay system for the renowned VIDAS® range. It will benefit clinical labs and food industries by providing results to help speed up patient care and protect consumers.
-
15 Dec 2022
Financial Information
2022 increased outlook and 2023 preview guidance
bioMérieux, a world leader in the field of in vitro diagnostics, today released its adjusted outlook for full-year 2022 and a preview of 2023 guidance.
-
16 Nov 2022
Antimicrobial Resistance
Survey bioMérieux OpinionWay - Antimicrobial Resistance and diagnostic tests
To mark World Antimicrobial Awareness Week organized by the WHO from November 18-24, bioMérieux presents the results of a bioMérieux/OpinionWay survey on the general public's knowledge of antimicrobial resistance and the use of diagnostic tests in France.
-
26 Oct 2022
Financial Information
Third-quarter 2022 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, releases its business review for the nine months ended September 30, 2022.
-
26 Sep 2022
Sepsis
New survey shows low adherence to guidelines in sepsis care puts patients at risk
Marcy l’Étoile, France and London, UK – To mark Sepsis Awareness Month, bioMérieux, a world leader in in vitro diagnostics with a long-standing commitment to the fight against sepsis, and the UK Sepsi...